Yes. Paxlovid has been a remarkable drug until now, as we know, and, as you of all people know, the initial clinical evidence was strong. It has been increasingly available in clinical settings across Canada. It started a bit slow, because provinces and territories initially found it a bit challenging, let's say, as always happens, to make sure the drug was available in the right places, but we can be very proud of the outcomes they have achieved in the last few months.
Added to that is Evusheld, which is another therapeutic that is more particularly available for vulnerable populations that may not respond well to COVID-19 vaccines. That's also something very good from a clinical but also a social and public health perspective. We have other tools in our tool kit that we're hoping to bring forward.